Loading stock data…
AZN
$184.74-2.63 (-1.40%)
Market ClosedLast close May 1
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AstraZeneca PLC in the Healthcare sector is trading at $184.74. The stock is currently 13% below its 52-week high of $212.71, remaining 5.0% above its 200-day moving average. Technical signals show oversold RSI of 25 and bearish MACD signal, explaining why AZN maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 25) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$184.74
Potential Downside
28%
Whystock Fair Value$132.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$223.79+21.1%
Range$184.00 – $243.00
Fundamentals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$302.01B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.74
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Strong income play. Yield provides a meaningful total return floor.
161.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.04%
Volume
Today's trading volume
1.69M
Recent News
Amgen's Q1 Earnings Top Estimates, 16 Drugs Deliver Double-Digit Gains
AMGN beats Q1 estimates as 16 drugs post double-digit growth, offsetting biosimilar erosion and weaker legacy products while lifting 2026 outlook.
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.
AstraZeneca stock falls after FDA panel rejects breast cancer drug
An FDA advisory committee voted 6-3 against camizestrant, citing concerns about the trial design and whether patients benefit long-term
AstraZeneca shares drop after US regulators vote against breast cancer drug
<body><p>STORY: AstraZeneca shares fell close to 2% on Friday (May 1).</p><p>Investors sold off after the British drugmaker had a regulatory setback in the U.S overnight.</p><p>The U.S. Food and Drug Administration voted against recommending AstraZeneca's experimental breast cancer treatment.</p><p>It led to some doubts over approvals for the drug camizestrant.</p><p>The regulators cited concerns about study design rather than safety or efficacy itself.</p><p>Analysts argued this suggests the drug could still win approval based on data from other trials.</p><p>AstraZeneca said they were disappointed over the vote.</p><p>But they were still confident in the drug's potential and would continue working with the FDA.</p><p>Shares of the drugmaker have gained nearly 30% over the past year despite Friday's pullback.</p></body>
AstraZeneca falls as FDA advisers reject breast cancer drug use
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 1.9% to 13,688p after the US regulator's advisory panel declined to back its camizestrant treatment in a key breast cancer setting. The FTSE 100 drugmaker said the Oncologic Drugs Advisory Committee of the Food and Drug Administration (FDA)...